Document is current
Any future updates will be listed below
-
Authors
Mallery, Kevin
Bristow, Nathaniel R.
Heller, Nicholas
Travadi, Yash
Arafa, Ali
Kamalanathan, Kaylee
Galeano-Garces, Catalina
Ahmadi, Mahdi
Schaap, Grant
Hesch, Alexa
Hedeen, Olivia
Izuora, Zikora
Hapke, Joel
Miller, Jeffrey
Viswanathan, Arjun
Babris, Ivo
Bae, Songyi
Bhattacharya, Baisali
Le, Tuan
Clacko, Tony
Antonarakis, Emmanuel S.
Konety, Badrinath R.
Drake, Justin M.
Hong, Jiarong
-
Funding
Funding for this research was provided by:
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Institutes of Health (R41CA268344)
National Cancer Institute (P30 CA077598)
U.S. Department of Defense (W81XWH-22-2-0025)
- License Information
-
More Information
Article History
Received: 13 January 2026
Accepted: 14 February 2026
First Online: 14 April 2026
Competing interests
: A subset of the authors (K.M., N.R.B., N.H., Y.T., K.K., C.G.G., M.A., G.S., A.H., O.H., Z.I., J.H., J.M., A.V., I.B., S.B., T.L., T.C., B.R.K., J.M.D., J.H.) are employed by and have an equity stake in Astrin Biosciences which is actively seeking to commercialize the technology described in this paper. E.S.A. reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, MacroGenics, Merck, Pfizer, AstraZeneca, and Clovis; personal fees from Aadi Bioscience, Aikido Pharma, Astellas, Amgen, Blue Earth, Boundless Bio, Corcept Therapeutics, Exact Sciences, Hookipa Pharma, Invitae, Eli Lilly, Foundation Medicine, Menarini-Silicon Biosystems, Tango Therapeutics, Tempus and Z-alpha; grants from Novartis, Celgene, and Orion; and has a patent for an AR-V7 biomarker technology that has been licensed to Qiagen.
